Immunovirological follow-up and safety of HIV-infected patients receiving lenacapavir under compassionate access in France between 01/01/2021 and 12/31/2023
Retrospective descriptive cohort of patients who received Lenacapavir under compassionate access in France with 50 patients in 25 sites in France
Study Type
OBSERVATIONAL
Enrollment
58
Centre Hospitalier de la Côte Basque
Bayonne, France, France
Hôpital Béclère
Clamart, France, France
proportion of participants with plasma HIV RNA < 50 copies/ml 26 weeks after first LEN injection
Time frame: Week 26
incidence of side effects and laboratory abnormalities on LEN treatment
Time frame: between week 26 and Week 52
evolution of HIV-1 or HIV-2 RNA over time
Time frame: between week 26 and Week 52
evolution of CD4, CD8 lymphocyte counts and CD4/CD8 ratio over time
Time frame: between week 26 and Week 52
Proportion of patients with capsid resistance mutations emergence at time of virological failure response) compared with initiation (D0)
Time frame: between Week 26 and Week 52
Determination by multivariate analysis of factors associated with virological success 26 weeks after the first LEN injection factors associated with virological control 26 weeks after the first LEN injection
Time frame: Week 26
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hôpital de la Rochelle
La Rochelle, France, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, France, France
Hôpital Max Fourestier
Nanterre, France, France
CHU La Source
Orléans, France, France
Hôpital Félix Guyon
Saint-Denis, LA Reunion, France
Hopital Zobda Quitman
Fort-de-France, Martinique, France
Hopital Avicenne
Bobigny, France
Hôpital Pellegrin - Service de Médecine Interne et Maladies Infectieuses
Bordeaux, France
...and 13 more locations